30 results about "Factor D" patented technology

The present invention is concerned with new compounds, and particularly those having a fused bicyclic ring substituted with an amidine moiety. These compounds are each potent inhibitors of Factor D of the alternate pathway of complement, C1s of the classical pathway of complement, Factors Xa, XIIa, VIIa and thrombin of the coagulation pathway, plasmin in the fibrinolytic pathway, and kallikrein and high molecular weight kininogen in the inflammatory pathways. These proteases, which have serine in their active site, are called serine proteases and they are pivotal to most of the processes of inflammation and coagulation. In fact, these various systems are interactive with one another and it is difficult to activate one pathway without it influencing the others.

A method for preventing or treating meconium aspiration syndrome (“MAS”) by administering a meconium aspiration syndrome preventing or treating amount of one or more complement inhibitors to a patient likely to develop or suffering from MAS. The complement inhibitors are preferably antibodies that bind to and inhibit complement proteins involved in the formation of the membrane attach complex, preferably anti-Factor D or anti-C5 antibodies. The complement inhibitors can be used alone or in combination with other MAS therapies to decrease the morbidity and mortality caused by MAS.

The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.

Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R¹² or R¹³ on the A group is an amide substituent (R³²) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade in the alternative complement pathway. The inhibitors of factor D described herein reduce the excessive activation of complement.

The invention provides methods and compositions for treating various degenerative diseases (e.g., AMD) with a factor D inhibitor (e.g., anti-factor D antibody or antigen-binding fragment thereof). Also provided are methods of selecting or identifying patients for treatment with a factor D inhibitor. Methods include the use of prognostic and/or predictive biomarkers.

The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease.

A method for treating a subject suffering from age related illnesses such as Type 2 diabetes by administering to the subject a compound to down regulate Factor D or Factor H thereby providing prophylaxis and therapy to inhibit age related illnesses. The compound is a functionalized Nano Polymer of less than 100 nm, which primarily inhibits Factor D, Factor H, or both.

The invention discloses a nicandra physalodes stem total alkaloid extraction process. The extraction process includes the step A of standard solution preparation: accurately weighing 5.5mg of standardatropine sulfate with a 1/10000 scale, and metering the volume with ethanol into a 50 ml volumetric flask to prepare 0.11mg.mL-1 standard solution. First a single factor test is carried out to determine the optimal extraction conditions, and then an orthogonal test is designed based on the optimal extraction conditions obtained by the single factor test. By calculating the alkaloid yield, the nicandra physalodes stem total alkaloid ultrasonic extraction optimal process conditions are obtained: ultrasonic 50min; ratio of material to liquid 1:25; ethanol concentration 60%; ultrasonic power 400w; temperature 50 DEG C; extraction rate 2.58%. The influence of a factor A, a factor B, a factor C, a factor D and a factor E can be analyzed according to analysis of variance, the sequence is that B>A>D>E>C, that is, time>material ratio>concentration>power>temperature.

The invention provides anti-Factor D antibodies and conjugates and methods of using the same.

The invention discloses a method for enriching target DNA fragments by multiple PCR. The method for enriching target DNA fragments disclosed by the invention includes: carrying out multiplex PCR for enriching target DNA fragments by using a complete set of primers meeting the following conditions: factor J of each primer pair < 50% and at most one factor of nine factors is not in the standard range; the standard ranges of the nine factors are: 35% <= factor A <= 60%; 68 DEG C <= factor B <= 79 DEG C; 30% <= factor C <= 70%; 30% <= factor D <= 70%; 15 kcal/mol <= absolute value of factor E <= 70 kcal/mol; absolute value of factor F < 100 kcal/mol; absolute value of factor G < 100 kcal/mol; 4 kcal/mol <= absolute value of factor H <= 10 kcal/mol; and factor I < 100 DEG C. The method of the invention can be used to successfully enrich target DNA fragments in genome.

A method for the diagnosis of C3NeF-mediated membranoproliferative glomerulonephritis (MPGN) in a sample may include the step of immobilization of C3b in at least two wells of a plate. The method may further include formation in the wells of the C3bBb complex, where the formation of the complex is mediated by the addition of IgGs purified from the sample and/or control in the presence of Factor B (FB), Factor D (FD), bovine serum albumin (BSA), or magnesium ions. The method may also include detachment of the formed complexes and an electrophoretic run under denaturing conditions of the complexes and transfer on a membrane. Further, the method may include detection of the protein of interest, Bb. The ratio of the intensities measured for the Bb band in the samples collected by each of the wells is indicative of C3NeF activity in the sample.